Project Grant HT94252410513
Award Date
9/30/24
Completion Date
9/29/28
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,453,501.00 Project Grant to The Regents of the University of California, San Francisco (UCSF) on June 1, 2024. The grant supports the development of "Targeted Theranostic Nanopolymers for Imaging and Alpha Radiopharmaceutical Therapy of Prostate Cancer" over a period of 3 years through May 31, 2027. As a leading academic medical center, UCSF will leverage its expertise in biomedical...
The Defense Health Agency awarded a $1,453,500.00 Project Grant to The Regents of the University of California, San Francisco (UCSF) under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, commencing on June 20, 2023, will support UCSF's research to profile and eliminate tumor subclones resistant to radioligand therapy. Through this project, UCSF aims to transform health care for Service Members and the American public by developing innovative and...
The University of California, San Francisco (UCSF) has been awarded a $1,202,087 federal Project Grant from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to investigate SSTR1 as a novel biomarker and therapeutic target in advanced prostate cancer. The award, effective July 1, 2024 through June 30, 2028, will enable UCSF researchers to conduct innovative scientific studies to develop new treatments for this challenging disease. As a leading academic...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,615,000.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at "DISCOVERING TRANSCRIPTIONAL DRIVERS OF THERAPY-RESISTANT METASTATIC PROSTATE CANCER". The award period runs from May 1, 2024 to April 30, 2027. As a leading academic medical center, UCSF has a strong track record of...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $1,967,999.00 to The Regents of the University of California, San Francisco (UCSF) for the development of a CD46 targeted antibody fragment radiopharmaceutical therapy for the treatment of prostate cancer. The award period runs from July 1, 2025 to June 30, 2028. This research aims to advance disease prevention, diagnosis, treatment, and management of...
The Regents of the University of California, San Francisco was awarded a $484,500 Project Grant from the Defense Health Agency to support research titled "Synergistic Combination Treatment of Prostate Cancer Using CD46- Targeted Antibody-Drug Conjugate and Radioimmunotherapy." The two-year award beginning March 1, 2023 will fund the development of innovative medical solutions for prostate cancer through the Military Medical Research and Development program (CFDA 12.420). This program...
This federal Project Grant award of $1,041,595.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports advanced biomedical research focused on transforming healthcare for military service members and the broader public. The grant funds The Regents of the University of California, San Francisco (UCSF) to conduct research across multiple medical disciplines, including cancer research, neuroscience, rare diseases,...
This federal Project Grant award of $1,008,313.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support advanced biomedical research by The Regents of the University of California, San Francisco (UCSF). The award, effective September 1, 2024 through August 31, 2027, will fund UCSF's research focused on transforming healthcare for military service members and the broader public. The research aims to advance disease prevention,...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,228,594.00 to the Regents of the University of California, San Francisco (UCSF) for research on bispecific antibody-drug conjugates against emerging targets in metastatic lethal prostate cancer. The award period is from April 15, 2024 to April 14, 2027. As a leading academic medical center and research institution, UCSF will leverage its...
The Department of the Army Medical Command awarded a $161,500 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Regents of the University of California, San Francisco (UCSF) to conduct research on "Deciphering Translational Control of Androgen Receptor in Prostate Cancer". The grant project will run from April 1, 2024 to March 31, 2026. As a leading academic medical center and research institution, UCSF has extensive expertise in federal...